Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

被引：0
|
作者：
Victoria Wurcel
Diana Chirovsky
Rebekah Borse
Juan Ignacio Altuna
Fernando Carabajal
Jyotika Gandhi
机构：
[1] MSD Argentina,
[2] Merck & Co.,undefined
[3] Inc.,undefined
[4] CHEORS,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Argentina; Cetuximab; Cost-effectiveness; Head and neck squamous cell carcinoma; Latin America; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2613 / 2630
页数：17
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Nunez, S. M.
    Godoy, J., I
    Cardona, A. F.
    Otero, J. M.
    Lujan, M.
    Lopera, D.
    Carranza, H.
    Spath, A.
    Gis, P. R.
    VALUE IN HEALTH, 2012, 15 (04) : A219 - A219
  • [42] Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States
    Monk, Bradley J.
    van Mens, Sophie
    Hale, Oliver
    Boer, Jennifer
    van Hees, Frank
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    ONCOLOGY AND THERAPY, 2025, 13 (01) : 85 - 98
  • [43] COST-EFFECTIVENESS OF PEMBROLIZUMAB FOR FIRST-LINE TREATMENT IN PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER IN THE UNITED STATES
    Monk, Bradley
    Boer, Jennifer
    Van Hees, Frank
    Van Mens, Sophie
    Swami, Shilpi
    Muston, Dominic
    Tekin, Cumhur
    Keefe, Steve
    Monberg, Matthew
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A38 - A38
  • [44] Cost-effectiveness of first-line treatments in metastatic renal cell carcinoma
    Benton, John Z.
    Klaassen, Zachary
    Wallis, Christopher J. D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (02) : 285 - 286
  • [45] Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer
    Hannouf, Malek B.
    Sehgal, Chander
    Cao, Jeffrey Q.
    Mocanu, Joseph D.
    Winquist, Eric
    Zaric, Gregory S.
    PLOS ONE, 2012, 7 (06):
  • [46] Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma
    Black, Christopher M.
    Hanna, Glenn J.
    Wang, Liya
    Ramakrishnan, Karthik
    Goto, Daisuke
    Turzhitsky, Vladimir
    Hair, Gleicy M.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
    Cirillo, Alessio
    Marinelli, Daniele
    Romeo, Umberto
    Messineo, Daniela
    De Felice, Francesca
    De Vincentiis, Marco
    Valentini, Valentino
    Mezi, Silvia
    Valentini, Filippo
    Vivona, Luca
    Chiavassa, Antonella
    Cerbelli, Bruna
    Santini, Daniele
    Bossi, Paolo
    Polimeni, Antonella
    Marchetti, Paolo
    Botticelli, Andrea
    BMC CANCER, 2024, 24 (01)
  • [48] Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
    Gui, L.
    He, X.
    Yang, J.
    Liu, P.
    Yan, Q.
    Shi, Y-K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S855 - S856
  • [49] Combined taxane, platinum, and cetuximab as a first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma: Retrospective study
    Liu, Yizhen
    Xue, Liqiong
    Xia, Zuguang
    Zhang, Qunling
    Guo, Ye
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2022, 44 (09): : 2040 - 2045
  • [50] Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
    Harrington, K. J.
    William, W. N., Jr.
    Khilnani, A.
    Algazi, A. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S683
12345